Securing comparator drugs in the EU is a complex process shaped by availability constraints, regulatory expectations, and competitive market behavior. But if we have the right planning, strong ...
IM1240 demonstrated improved safety in a toxicology study at doses up to 300-fold higher than a non-capped comparator ...
DCN Dx, a specialist in diagnostics development, manufacturing, regulatory consulting, and clinical research, today announced the launch of a new prospective biospecimen collections offering, ...
The ISPOR Glasgow panel conveyed a constructive, forward looking mood: JCA can work – and work better over time – if ...
The Financial Conduct Authority (FCA) has published updated proposals to its Value for Money (VFM) Framework consultation.
Why Elecnor (BME:ENO) is on investors’ radar Elecnor (BME:ENO) has drawn fresh attention after recent share price moves, with ...
CG Oncology develops cretostimogene via rolling BLA, phase 3 PIVOT-006 data in 1H 2026, and $680M cash into 2028. Find out ...
On track to define optimal dosing interval and advance manufacturing scale up of REYOBIQ for pivotal trial readiness in late ...
Newly diagnosed patients with KRAS G12C-mutant advanced or metastatic nonsquamous NSCLC will be enrolled in the trial.
The UK government and trust-based pensions regulator have backed new value for money proposals for the defined contribution ...
After unsheathing just a few months ago, Ollin Biosciences’ next-gen bispecific antibody cleared more disease faster than ...
Financial Conduct Authority (FCA), and The Pensions Regulator (TPR) have launched a consultation on the value for money (VfM) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback